Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 10:42 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Tardive Dyskinesia Clear all

Conditions: Tardive Dyskinesia
Interventions: Not listed
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 34
States / cities: Little Rock, Arkansas • Anaheim, California • Long Beach, California + 29 more

Conditions: Fibromyalgia, Mitochondrial Diseases, Movement Disorders, Diabetes Mellitus, Type 2
Interventions: Metformin; Drug
Lead sponsor: Woodinville Psychiatric Associates; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Woodinville, Washington

Conditions: Dyskinesia, Drug-Induced
Interventions: Quetiapine, Risperidone, Olanzapine; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 40 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: San Diego, California

Conditions: Tardive Dyskinesia
Interventions: Valbenazine; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 27
States / cities: Anaheim, California • National City, California • Norwalk, California + 24 more

Conditions: Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities
Interventions: Valbenazine Oral Capsule; Drug
Lead sponsor: Stephen Ruedrich; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Tardive Dyskinesia
Interventions: NBI-98854, Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 49
States / cities: Little Rock, Arkansas • Anaheim, California • Carson, California + 41 more

Conditions: Tardive Dyskinesia
Interventions: Not listed
Lead sponsor: Power Life Sciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Schizophrenia, Schizoaffective Disorder, Tobacco Smoking, Tardive Dyskinesia, Parkinsonism
Interventions: Varenicline; Drug
Lead sponsor: Corporal Michael J. Crescenz VA Medical Center; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Tardive Dyskinesia
Interventions: Valbenazine; Drug
Lead sponsor: Yale University; Other
Eligibility: 26 Years to 84 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Tardive Dyskinesia
Interventions: NBI-98854, Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 11
States / cities: Little Rock, Arkansas • National City, California • San Diego, California + 6 more

Conditions: Tardive Dyskinesia
Interventions: Galantamine; Drug
Lead sponsor: Caroff, Stanley N., M.D.; Individual
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Akathisia
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 60 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 1996 – 1999
U.S. locations: 2
States / cities: Morganton, North Carolina • University Park, Pennsylvania

Conditions: Tardive Dyskinesia
Interventions: NBI-98854, Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 21
States / cities: Costa Mesa, California • Fountain Valley, California • Oceanside, California + 17 more

Conditions: Tardive Dyskinesia (TD)
Interventions: Valbenazine, Placebo oral capsule; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 42
States / cities: Little Rock, Arkansas • Anaheim, California • Costa Mesa, California + 35 more

Conditions: Tourette Syndrome, Tardive Dyskinesia
Interventions: Pimavanserin; Drug
Lead sponsor: Joseph Jankovic; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Tardive Dyskinesia
Interventions: NBI-98854, Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 48
States / cities: Little Rock, Arkansas • Anaheim, California • Glendale, California + 45 more

Conditions: Drug-induced Tardive Dyskinesia
Interventions: SNC-102, Placebo; Drug
Lead sponsor: Synchroneuron Inc.; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Oral Dystonia, Tardive Dystonia
Interventions: Low Dose - AbobotulinumtoxinA; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Tardive Dyskinesia
Interventions: SD-809, Placebo; Drug
Lead sponsor: Auspex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 53
States / cities: Tuscaloosa, Alabama • Anaheim, California • Glendale, California + 43 more

Conditions: Tardive Dyskinesia
Interventions: NBI-1065890, Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 30
States / cities: Bryant, Arkansas • Chino, California • Fountain Valley, California + 26 more

Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia
Interventions: Valbenazine; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 19
States / cities: Bryant, Arkansas • Chino, California • Fresno, California + 16 more

Conditions: Tardive Dyskinesia (TD)
Interventions: Valbenazine, Placebo oral capsule; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 16
States / cities: Anaheim, California • Glendale, California • Norwalk, California + 11 more

Conditions: Tardive Dyskinesia
Interventions: TDtect; Other
Lead sponsor: iRxReminder; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Brooklyn, New York • Garfield Heights, Ohio

Conditions: Tardive Dyskinesia
Interventions: Two way video assessment; Other
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 75 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Glen Oaks, New York

Search by objective public record fields.

Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents

Heart Rate Variability in Response to Metformin Challenge

Movement Disorders Caused by Antipsychotic Drugs in Older Patients

Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia

Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities

NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)

Studying Patterns in Patient Engagement Among Tardive Dyskinesia Patients

Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates

Reduction of Demoralization in Patients With Tardive Dyskinesia After Treatment With Valbenazine

NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder

Treatment of Tardive Dyskinesia With Galantamine

Akathisia (Restless Legs Syndrome) in People With Schizophrenia and Mental Retardation

NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia

Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia

Pimavanserin Treatment in TS

A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia

A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive Dyskinesia

Dysport for the Treatment of OMD

Addressing Involuntary Movements in Tardive Dyskinesia

Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia

A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine

Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient Outcomes

The Assessment of Movement Disorders Utilizing Live Two-Way Video